The firm’s stent system, called Vici, was designed to overcome the challenges of durability and ease of use physicians face when working with stents with the millions of patients affected by venous disease worldwide, according to a statement from Veniti.
The FDA Investigational Device Exemption study will include 200 patients and take place over the course of 60 months to ensure patient safety post-surgery.
Last year, Veniti raised more than $17 million from various life sciences venture capital firms to demonstrate patient benefit from its Vici stent system.
More articles on medical devices:
FDA investigates St. Jude Medical’s cardiac devices for potential security flaws
Medicaid rebates for Mylan’s EpiPen challenged by US lawmakers
Nestlé to acquire medical device company Phagenesis: 4 things to know
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
